Nanotechnology Reprogramming Metabolism for Enhanced Tumor Immunotherapy
ACS Nano · 23.01.2024 · 18 (3) · 1846-1864
DOI: 10.1021/acsnano.3c11260 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ACS Nano, online erschienen am 05.01.2024. Verfasst von Yangkai Zhou und 4 weiteren Autor:innen. Beteiligte Einrichtung: CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety & CAS Center for Excellence in Nanoscience, National Center for Nanoscience…. Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 70-mal zitiert (Crossref) und nennt 202 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety & CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing 100190, China.
- University of Chinese Academy of Sciences, Beijing 100049, China.
- First Medical Center of Chinese PLA General Hospital, Beijing 100853, China.
ORCID-Profile: Ying Liu
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Zhou, Y., Yuan, J., Xu, K., Li, S., & Liu, Y. (2024). Nanotechnology Reprogramming Metabolism for Enhanced Tumor Immunotherapy. ACS Nano, 18(3), 1846-1864. https://doi.org/10.1021/acsnano.3c11260
Vancouver
Zhou Y, Yuan J, Xu K, Li S, Liu Y. Nanotechnology Reprogramming Metabolism for Enhanced Tumor Immunotherapy. ACS Nano. 2024;18(3):1846-1864. doi:10.1021/acsnano.3c11260
BibTeX
@article{Zhou2024,
author = {Zhou, Yangkai and Yuan, Jing and Xu, Ke and Li, Shilin and Liu, Ying},
title = {Nanotechnology Reprogramming Metabolism for Enhanced Tumor Immunotherapy},
journal = {ACS Nano},
year = {2024},
volume = {18},
number = {3},
pages = {1846--1864},
doi = {10.1021/acsnano.3c11260}
}
EUVIMED